Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats

Toxicology

Volumn 250, Issue 2-3, 2008, Pages 100-108

  Crincoli, Christine M ^a   Patel, Niti N ^a   Tchao, Ruy ^a   Harvison, Peter J ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

3 (3,5 Dichlorophenyl) 2,4 thiazolidinedione; Hepatotoxicity; Rats; Thiazolidinediones

Indexed keywords

1 AMINOBENZOTRIAZOLE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (3,5 DICHLOROPHENYL) 2,4 THIAZOLIDINEDIONE; ALANINE AMINOTRANSFERASE; CYTOCHROME P450 3A; DEXAMETHASONE; ETHOXYRESORUFIN DEETHYLASE; PENTOXYRESORUFIN DEALKYLASE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; EXPERIMENTAL MODEL; FISCHER 344 RAT; KIDNEY; LIVER INJURY; LIVER MICROSOME; LIVER NECROSIS; LIVER TOXICITY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TOXICITY TESTING; TOXICOKINETICS; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WESTERN BLOTTING;

ANIMALS; BIOTRANSFORMATION; BLOOD UREA NITROGEN; BLOTTING, WESTERN; BODY WEIGHT; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FUNGICIDES, INDUSTRIAL; HEPATITIS, TOXIC; HYDROXYLATION; INDICATORS AND REAGENTS; MALE; MICROSOMES, LIVER; ORGAN SIZE; RATS; RATS, INBRED F344; TESTOSTERONE; THIAZOLIDINEDIONES;

ANIMALIA; RATTUS;

EID: 49849099627     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.06.006     Document Type: Article

References (39)

1. Alvárez-Sanchez R., Montavon F., Hartung T., and Pähler A. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem. Res. Toxicol. 19 (2006) 1106-1116
2. Arlotto M.P., Trant J.M., and Estabrook R.W. Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods Enzymol. 206 (1991) 454-462
3. Baughman T.M., Graham R.A., Wells-Knecht K., Silver I.S., Tyler L.O., Wells-Knecht M., and Zhao Z. Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab. Dispos. 33 (2005) 733-738
4. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Chem. 72 (1976) 248-254
5. Bruno G., Costantino L., Curinga C., Maccari R., Monforte F., Nicolò F., Ottanà R., and Vigorita M.G. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem. 10 (2002) 1077-1084
6. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., and Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48 (1994) 923-936
7. Buters J.T., Korzekwa K.R., Kunze K.L., Omata Y., Hardwick J.P., and Gonzales F.J. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab. Dispos. 22 (1994) 688-692
8. Caron E., Rioux N., Nicolas O., Lebel-Talbot H., and Hamelin B.A. Quantification of the expression and inducibility of 12 rat cytochrome P450 isoforms by quantitative RT-PCR. J. Biochem. Mol. Toxicol. 19 (2005) 368-378
9. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 41 (2005) 237-246
10. Cullen J.M. Mechanistic classification of liver injury. Toxicol. Pathol. 33 (2005) 6-8
11. Fujinami A., Ozaki T., and Yamamoto T. Antimicrobial activity of 3-phenyloxazolidine-2,4-diones and related compounds. Agric. Biol. Chem. 35 (1971) 1707-1719
12. Gale E.A.M. Lessons from the glitazones: a story of drug development. Lancet 357 (2001) 1870-1875
13. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., and Juarbe H.M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129 (1998) 36-38
14. Gouda H.E., Khan A., Schwartz J., and Cohen R.I. Liver failure in a patient treated with long-term rosiglitazone therapy. Am. J. Med. 111 (2001) 584-585
15. He K., Talaat R.E., Pool W.F., Reily M.D., Reed J.E., Bridges A.J., and Woolf T.F. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32 (2004) 639-646
16. Kassahun K., Pearson P.G., Tang W., McIntosh I., Leung K., Elmore C., Dean O., Wang R., Doss G., and Baillie T.A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinine methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14 (2001) 62-70
17. Kato R., and Yamazoe Y. Sex-specific cytochrome as a cause of sex- and species-related differences in drug toxicity. Toxicol. Lett. 64/65 (1992) 661-667
18. Kennedy E.L., Tchao R., and Harvison P.J. Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione-, and thiazolidinedione-containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats. Toxicology 186 (2003) 79-91
19. Kohlroser J., Mathai J., Reichheld J., Banner B.F., and Bonkovsky H.L. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. J. Gasteroenterol. 95 (2000) 272-276
20. Kostrubsky V.E., Szakacs J.G., Jeffery E.H., Wood S.G., Bement W.J., Wrighton S.A., Sinclair P.R., and Sinclair J.F. Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. Toxicol. Appl. Pharmacol. 143 (1997) 315-323
21. Lake B.G. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. In: Snell K., and Mullock B. (Eds). Biochemical Toxicology: A Practical Approach (1987), IRL Press, Oxford 183-215
22. Lin G., Cui Y.Y., and Liu X.Q. Gender differences in microsomal metabolic activation of hepatotoxic clivorine in rat. Chem. Res. Toxicol. 16 (2003) 768-774
23. Lindros K.O. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen. Pharmacol. 28 (1997) 191-196
24. Maeda K. Hepatocelluar injury in a patient receiving pioglitazone. Ann. Intern. Med. 135 (2001) 306
25. Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet. 21 (2006) 347-356
26. Mugford C.A., Mortillo M., Mico B.A., and Tarloff J.B. 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Fundam. Appl. Toxicol. 19 (1992) 43-49
27. Murray M. Glucocorticoid-dependent maintenance of CYP2C11-dependent oxidation in male rat liver in vivo. Human Exp. Toxicol. 19 (2000) 126-131
28. Ong M.M.K., Latchoumycandane C., and Boelsterli U.A. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 97 (2007) 205-213
29. Patel N.N., Crincoli C.M., Kennedy E.L., Frederick D.M., Tchao R., and Harvison P.J. Effect of gender, dose and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats. Xenobiotica 38 (2008) 435-449
30. Rakowitz D., Maccari R., Ottanà R., and Vigorita M.G. In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones. Bioorg. Med. Chem. 14 (2006) 567-574
31. Reddy V.B., Karanam B.V., Gruber W.L., Wallace M.A., Vincent S.H., Franklin R.B., and Baillie T.A. Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols. Chem. Res. Toxicol. 18 (2005) 880-888
32. Scheen A.J. Hepatotoxicity with thiazolidinediones: is it a class effect?. Drug Saf. 24 (2001) 873-888
33. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16 (2003) 679-687
34. Stine E.R., Gunawardhana L., and Sipes I.G. The acute hepatotoxicity of the isomers of dichlorobenzene in Fischer-344 and Sprague-Dawley rats: isomer-specific and strain-specific differential toxicity. Toxicol. Appl. Pharmacol. 109 (1991) 472-481
35. Tang W., Stearns R.A., Bandiera S.M., Zhang Y., Raab C., Braun M.P., Dean D.C., Pang J., Leung K.H., Doss G.A., Strauss J.R., Kwei G.Y., Rushmore T.H., Chiu S.H., and Baillie T.A. Studies on cytochrome P-450-mediated biotransformation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug. Metab. Dispos. 27 (1999) 365-372
36. Tettey J.N., Maggs J.I., Rapeport W.G., Piromohamed M., and Park B.K. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14 (2001) 965-974
37. Thogmartin J.R., England D., and Siebert Jr. C.F. Hepatic glycogen staining. Applications in injury survival time and child abuse. Am. J. Forensic Med. Pathol. 22 (2001) 313-318
38. Valentovic M.A., Ball J.G., Anestis D., and Madan E. Acute hepatic and renal toxicity of dichlorobenzene isomers in Fischer 344 rats. J. Appl. Toxicol. 13 (1993) 1-7
39. Venkatakrishnan K.J., von Moltke L.L., and Greenblatt D.J. Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models. J. Clin. Pharmacol. 41 (2001) 1149-1179